BRPI0819678A2 - método para tratar cmt e distúrbios relacionados - Google Patents

método para tratar cmt e distúrbios relacionados

Info

Publication number
BRPI0819678A2
BRPI0819678A2 BRPI0819678A BRPI0819678A BRPI0819678A2 BR PI0819678 A2 BRPI0819678 A2 BR PI0819678A2 BR PI0819678 A BRPI0819678 A BR PI0819678A BR PI0819678 A BRPI0819678 A BR PI0819678A BR PI0819678 A2 BRPI0819678 A2 BR PI0819678A2
Authority
BR
Brazil
Prior art keywords
related disorders
treating cmt
cmt
treating
disorders
Prior art date
Application number
BRPI0819678A
Other languages
English (en)
Inventor
Cohen Daniel
Chumakov Ilya
Guerassimenko Oxana
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of BRPI0819678A2 publication Critical patent/BRPI0819678A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0819678A 2007-11-30 2008-11-28 método para tratar cmt e distúrbios relacionados BRPI0819678A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
BRPI0819678A2 true BRPI0819678A2 (pt) 2017-05-09

Family

ID=39264515

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819678A BRPI0819678A2 (pt) 2007-11-30 2008-11-28 método para tratar cmt e distúrbios relacionados

Country Status (24)

Country Link
US (6) US8992891B2 (pt)
EP (4) EP2065038A1 (pt)
JP (4) JP5953000B2 (pt)
KR (1) KR101546031B1 (pt)
CN (2) CN104257657B (pt)
AU (1) AU2008328745B2 (pt)
BR (1) BRPI0819678A2 (pt)
CA (3) CA3031484C (pt)
CY (2) CY1113980T1 (pt)
DK (2) DK2609916T3 (pt)
EA (3) EA035711B1 (pt)
ES (3) ES2703508T3 (pt)
HR (2) HRP20130345T1 (pt)
HU (1) HUE040596T2 (pt)
IL (1) IL205741A0 (pt)
LT (1) LT2609916T (pt)
MX (1) MX2010005709A (pt)
NZ (1) NZ585440A (pt)
PL (2) PL2609916T3 (pt)
PT (2) PT2609916T (pt)
SI (2) SI2211846T1 (pt)
TR (1) TR201819564T4 (pt)
WO (1) WO2009068668A1 (pt)
ZA (1) ZA201003610B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2502079B1 (en) * 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
JP5914357B2 (ja) 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物
CA2812855C (en) * 2010-10-08 2017-12-19 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
WO2014063163A1 (en) 2012-10-19 2014-04-24 Block Jonathan D Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
KR20160126045A (ko) * 2014-02-24 2016-11-01 파넥스트 기계적 신경 손상을 치료하기 위한 신규 조성물
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
AU2017229778A1 (en) 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2018014007A1 (en) * 2016-07-14 2018-01-18 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
CA3044691A1 (en) * 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
KR20230005944A (ko) * 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
EP1020193A4 (en) 1997-09-30 2006-05-24 Daiichi Seiyaku Co ORAL PREPARATION
EP1115864A2 (en) * 1998-09-22 2001-07-18 Incyte Genomics, Inc. Human chaperone proteins
WO2000020024A2 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
AU2003220290B2 (en) * 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
PT1578350E (pt) * 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
JP2006504679A (ja) 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
KR20120066688A (ko) * 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
PL2368554T3 (pl) * 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
MXPA06003392A (es) * 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
RS53227B (sr) 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
EA201791669A2 (ru) 2017-12-29
CA3031484A1 (en) 2009-06-04
DK2609916T3 (en) 2019-01-21
US20180250289A1 (en) 2018-09-06
EP3459535B1 (en) 2020-08-12
JP2018109043A (ja) 2018-07-12
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
JP5953000B2 (ja) 2016-07-13
HUE040596T2 (hu) 2019-03-28
CN104257657A (zh) 2015-01-07
HRP20130345T1 (hr) 2013-07-31
EP2211846B1 (en) 2013-02-27
CA3031490C (en) 2021-05-04
EA201791669A3 (ru) 2018-03-30
AU2008328745A1 (en) 2009-06-04
EP2211846A1 (en) 2010-08-04
HRP20182147T1 (hr) 2019-03-08
DK2211846T3 (da) 2013-04-29
EA201301078A1 (ru) 2014-06-30
WO2009068668A1 (en) 2009-06-04
HRP20182147T8 (hr) 2019-04-19
KR20100088160A (ko) 2010-08-06
US10441558B2 (en) 2019-10-15
CY1121183T1 (el) 2020-05-29
CA2705408A1 (en) 2009-06-04
KR101546031B1 (ko) 2015-08-25
US20180360785A1 (en) 2018-12-20
US20200155491A1 (en) 2020-05-21
SI2211846T1 (sl) 2013-07-31
CN101883561A (zh) 2010-11-10
CN104257657B (zh) 2017-07-04
CA2705408C (en) 2019-04-23
TR201819564T4 (tr) 2019-01-21
US8992891B2 (en) 2015-03-31
ES2408785T3 (es) 2013-06-21
CA3031490A1 (en) 2009-06-04
JP2011504915A (ja) 2011-02-17
EA019402B1 (ru) 2014-03-31
EP2609916B1 (en) 2018-11-07
CN101883561B (zh) 2014-07-30
MX2010005709A (es) 2010-11-05
ES2831855T3 (es) 2021-06-09
EP3459535A1 (en) 2019-03-27
CA3031484C (en) 2021-05-04
NZ585440A (en) 2011-12-22
ES2703508T3 (es) 2019-03-11
LT2609916T (lt) 2019-02-11
IL205741A0 (en) 2010-11-30
PL2609916T3 (pl) 2019-03-29
PT2211846E (pt) 2013-05-10
AU2008328745B2 (en) 2014-01-30
US20180338969A1 (en) 2018-11-29
EA032767B1 (ru) 2019-07-31
EA035711B1 (ru) 2020-07-29
US20150157626A1 (en) 2015-06-11
ZA201003610B (en) 2011-06-29
US20100310641A1 (en) 2010-12-09
EP2609916A1 (en) 2013-07-03
PT2609916T (pt) 2019-01-10
JP2019142917A (ja) 2019-08-29
EP2065038A1 (en) 2009-06-03
CY1113980T1 (el) 2016-07-27
US10322101B2 (en) 2019-06-18
EA201000914A1 (ru) 2010-12-30
JP2016145227A (ja) 2016-08-12
US10463640B2 (en) 2019-11-05
JP6608309B2 (ja) 2019-11-20

Similar Documents

Publication Publication Date Title
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0810718A2 (pt) Método e aparelho para a formação de múltiplos microcondutos
BRPI0808115A2 (pt) Método e aparelho para coexistência
BRPI0910587A2 (pt) método e aparelho para eletrogalvanização
PT2250275T (pt) Aparelho e método para tratar resíduos
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0907183A2 (pt) Método e entidade para encriptação simétrica probabilítica
BRPI0817292A2 (pt) Método e aparelho para completação de poços.
PT2178796T (pt) Método contínuo para tratamento de líquidos e fabrico de certos constituintes
BRPI0807958A2 (pt) Método e equipamento para handover inter-sistemas
BRPI0814841A2 (pt) Método e aparelho para fabricação d eum material compósito
BRPI0822972A2 (pt) "método e aparelho para redução de atrito"
BRPI0809132A2 (pt) método e aparelhos para pré-peneiramento
BRPI0907812A2 (pt) Aparelho e método para produzir uréia
BRPI0818056A2 (pt) Aparelho e métodos para hemodiálise
BRPI0914965A2 (pt) método e aparelho para melhoria de pcc para mobilidade baseada em fluxo
BRPI0815469A2 (pt) Não-tecido e método para produção do mesmo
BRPI0720677A2 (pt) Aparelho e método para produzir carvão.
BRPI0918294A2 (pt) dispositivo e método para produzir explosões
BRPI0913156A2 (pt) método e aparelho para acesso a link seguro direto
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
ZA201003610B (en) New therapeutic approaches for treating cmt and related disorders
BRPI0914862A2 (pt) método e dispositivo para colocação de implante
BRPI0814161A2 (pt) Método e aparelho para formar hastes de tabaco
BRPI0819351A2 (pt) Método e aparelho para utilização de hidrogênio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE.